ORIC Reports $420M Cash, $19M Net Income, +12% YoY, Rinzimetostat RP3D Selected for Himalayas-1 Phase 3 mCRPC Trial
Oric Pharmaceuticals, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $8.98
-11% in 7d after detection
Post-detection moves
1h
—
1d
-0.6%
3d
-8.5%
7d
-11%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS